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Background: MicroRNAs (miRNAs) are endogenous small (19–24 nt long) noncoding RNAs that regulate gene
expression in a sequence specific manner. An increasing association between miRNA and cancer has been recently
reported. Hepatocellular carcinoma (HCC), as the fifth most common cancer and the most common cause of death
in men, has become the third leading cause of cancer-related deaths globally. In this study, we investigated the
miR-9 expression in HCC to evaluate their value in prognosis of this tumor.
Methods: The expression of miR-9 in matched normal and tumor tissues of HCC was evaluated using a quantitative
real-time RT-PCR. A Kaplan–Meier survival curve was generated following a log-rank test.
Results: It was observed that miR-9 expression was upregulated in HCC tissues compared with noncancerous liver
tissues (7.26 ± 1.30 vs. 3.14 ± 1.08, P < 0.001). The up-regulation of miR-9 in HCC cancer tissues was also significantly
correlated with aggressive clinicopathological features. We found that the patients with high miR-9 expression have a
higher tumor staging (P = 0.0389) and are in higher risk of venous infiltration (P < 0.0001). Moreover, the results of
Kaplan–Meier analyses showed that HCC patients with the high miR-9 expression tend to have shorter overall survival
(P < 0.0001). The multivariate analysis clearly indicated that the high miR-9 expression in biopsy samples may be
considered as an independent prognostic factor in HCC for decreased survival (4.28; 95%CI, 2.77-7.23, P < 0.001).
Conclusion: Our data indicate the potential of miR-9 as a novel prognostic biomarker for HCC. Large well-designed
studies with diverse populations and functional evaluations are warranted to confirm and extend our findings.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_228Background
Hepatocellular carcinoma (HCC) has become the third
leading cause of cancer-related deaths globally [1]. The
incidence of HCC is still increasing in the developing
countries, especially in East and South-East Asia, with
the highest reported primary liver cancer rates. Annually,
more than 700,000 new cases are diagnosed worldwide
and unfortunately more than 600,000 cases dead due to
this cancer [2]. The five-year survival rate of this cancer is* Correspondence: lzcai_2014@163.com
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unless otherwise stated.merely 7% [3]. The development and progression of HCC
is a multistage process involving the deregulation of genes
that are crucial to cellular processes, such as cell cycle
control, cell growth, apoptosis and cell migration. HCC is
highly lethal because of its aggressive metastasis and an
advanced stage at the time of diagnosis. The occurrence
of HCC is a multi-factor and multi-stage process, includ-
ing both hereditary and environmental factors. Since the
diagnosis at early stage of HCC offers the only hope for
curative therapies, it is of utmost importance to screen
high-risk patients effectively. With the increasing under-
standing of tumor biology of HCC, recent studies haveThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sensitivity and specificity for diagnosis and prognosis in
patients with HCC.
MicroRNA (miRNA) belongs to a class of endogen-
ously expressed, non-coding small RNA and contains
about 22 nucleotides, which exhibits a high degree con-
servation of structure and function in metazoa. They
exist in two forms of pre-miRNAs and mature miRNAs,
and only the mature miRNAs mediated by the two
RNase III endonucleases Dicer and Drosha play a key
biological role [4]. The mature miRNAs inhibit protein
translation through binding the 3′-untranslated region
(3′-UTR) of target mRNA partly, while they induce tar-
get mRNA cleavage through binding mRNA with perfect
complementarity [5,6]. At present, approximately 450
miRNAs have been cloned in mammalian cells, and it is
believed that up to 1,000 miRNAs genes exist [7,8].
Moreover, it is estimated that 30% genes of the human
genome are regulated by miRNAs [9]. Though the bio-
logical functions of a small amount of identified miR-
NAs are elucidated, miRNAs have been proved to be
important for cell growth, differentiation, and apoptosis
[10,11]. miRNAs also regulate oncogenesis because they
are both oncogenic and tumor suppressors. miRNAs
regulate posttranscriptional expression of target genes
involved in any biological processes including develop-
ment, differentiation, cell proliferation, apoptosis, and
the stress response [12]. In addition, miRNAs are in-
volved in cancer development and progression and are
differentially expressed in normal tissues and cancers.
MiR-9 is a regulator of neuronal progenitor cell fate
during neurogenesis [13,14], which has recently been
implicated in cancer [15]. Although most studies indi-
cate a tumour-suppressor activity for miR-9 in cancer
cells [16], conflicting data exist, and the outcome of
miR-9 function appears to be tumour specific [17]. miR-
9 is downregulated in breast cancer, renal cell carcin-
oma, and gastric cancer due to promoter methylation
[18-20]. In contrast, miR-9 has been found to be upre-
gulated in gliomas and in colorectal cancer [21,22].
Recent studies also report that miR-9 is heterogeneously
expressed within a given tissue [23]. miR-9 has also
recently been shown to be associated with metastasisFigure 1 Tumor differentiation according to the Edmondson gradingformation in several cancer types, such as breast, colon,
ovarian, cervix, liver, and gastric cancer [16,22,24-26].
Recent studies have shown that miR-9 promotes metas-
tasis formation [22,24,26], however, in contrast, other
studies have suggested that increased expression of miR-
9 suppresses metastasis formation [16,25] and that miR-
9 inhibits tumor growth through inhibition of NFkappa
B1 [27,28]. Therefore, miR-9 might have different func-
tions in different cancers. In this study, we investigated
the miR-9 expression in HCC tissues to evaluate their
value in prognosis of this tumor.
Methods
Samples and cases
200 pairs of samples (including 200 HCC samples and
normal adjacent tissues) from HCC patients were col-
lected from April 2004 to April 2009 at the first affiliated
hospital of Yangtze University. None of the patients re-
cruited in this study had chemotherapy or radiotherapy
before the surgery. The miR-9 quantitative analysis
was performed with those samples via real-time PCR.
The study was approved by the first affiliated hospital
of Yangtze University. Written informed consent was
obtained for the acquisition and use of patient tissue
samples and anonymized clinical data.
The diagnosis and histological grade of each case were
confirmed by two pathologists independently. The clin-
ical stage was classified according to the Edmondson
grading system. Liver function was assessed using the
Child-Pugh scoring system. Tumor staging was deter-
mined according to the Union for International Cancer
Control (UICC) criteria (7th Edition) and WHO classifi-
cation (Pathology and Genetics of Tumors of the Digest-
ive System). Tumor differentiation was defined as poor,
moderate, and well according to the Edmondson grading
system (Figure 1).
RNA extraction
For real-time PCR analysis of miRNA, total RNA was
isolated using Trizol reagent (Invitrogen) according to
the manufacturer’s instructions. Briefly, plugs were
punched out (1.5 mm × 1.5 mm) of a paraffin block.
Samples were deparaffinized three times in 1 mL ACSsystem. Poor differentiation (a); Moderate (b); and Well (c).
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followed by a wash with 100% ACS grade ethanol and
air drying at room temperature. Samples were then incu-
bated with proteinase K (Merck) at 55°C overnight,
shaking every 2 h. RNA samples were resuspended in
RNase-free water after the final precipitation step. RNA
quality and quantity were assessed using a biophotome-
ter (Eppendorf ). The paraffin plugs were enriched for
tumor tissue under microscope control using H & E-
stained sections of the same sample for guidance.
The RNA concentration and purity were assessed by
UV spectrophotometry (A260/A280 ratio of 1.8 - 2.0).
Total RNA samples were reverse transcribed to cDNA
using a TaqMan® microRNA assay miRNA-specific stem-
loop primer and the TaqMan® microRNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA,
USA). The PCR was performed using the TaqMan® Uni-
versal PCR Master Mix and a 7500 Sequence Detection
System (Applied Biosystems) according to the manu-
facturer’s instructions, and previously published primer
sequences [29]. The cycling programme involved prelim-
inary denaturation at 95°C for 10 min, followed byFigure 2 miR-9 expression in 200 pairs of HCC and adjacent non-neo
chain reaction (qRT-PCR) analysis. (a) Comparison between all the HCC ti
HCC tissues and non-neoplastic tissues. (c) Comparison between advantaged
early and advantaged stage HCC tissues.40 cycles of denaturation at 95°C for 15 s, annealing at
60°C for 60 s and elongation at 60°C for 60 s. The U6
small nuclear (sn) RNA was amplified as an internal
control using previously published primer sequences.
Each sample was analysed in triplicate. Levels of miR-9
were analysed quantitatively relative to U6 snRNA by
the 2–ΔΔCT method using the equation, relative quantity
= 2–ΔΔCT, where ΔΔCT = (CT miR-21 - CT U6)cancer-
(CT miR-21 - CT U6) normal adjacent tissues, and CT is the
cycle threshold for each specimen.
Statistical analyses
To analyze baseline characteristics, the continuous vari-
ables was presented as Mean ± SD and compared between
groups by the Student’s t‑tests, and the categorical data
compared by Chi-square tests. Associations between miR-
9 expression and over survival of the patients with HCC
were estimated using adjusted relative risks and 95% confi-
dence intervals (95% CIs) from multivariate logistic regres-
sion. Survival time was calculated from the date of HCC
diagnosis to the date of death or last follow-up. Survival
analysis was estimated using the Kaplan–Meier method,platic liver tissues detected by quantitative real-time polymerase
ssues and non-neoplastic tissues. (b) Comparison between early stage
stage HCC tissues and non-neoplastic tissues. (d) Comparison between
Table 1 Correlation of miR-9 expression with
clinicopathological features of HCC (n = 200)






Age (year) <50 78 40 38 0.662
≥50 122 58 64
Gender Male 107 53 54 0.889
Female 93 45 48
Tumor size <5 cm 82 36 46 0.252
≥5 cm 118 62 56






Absent 131 82 49 <0.0001
Present 69 16 53
AFP level ≤20 ng/ml 45 27 18 0.127
>20 ng/ml 155 71 84
Table 2 Multivariate analyses of different prognostic
parameters in patients with HCC by Cox regression
analysis
Parameter Risk ratio1 95% CI2 P3
Age 1.60 0.40-2.65 0.667
Gender 1.53 0.50-2.95 0.754
Tumor size 2.25 0.95-4.34 0.078
AFP 1.38 0.58-2.64 0.430
Venous infiltration 2.61 1.34-5.12 0.006
miR-9 expression 4.28 2.77-7.23 <0.001
1RR; relative risk.
2CI; confidence interval.
3P-value,0.05 statistically significant and significant p-values are in bold.
Cai and Cai Diagnostic Pathology  (2014) 9:1000 Page 4 of 6log-rank test, and Cox-proportional hazards regression
model. The P < 0.05 was considered to indicate a statisti-
cally significant difference. The software of SPSS ver-
sion13.0 for Windows (SPSS, Inc., Chicago, IL) was used
for statistical analysis.
Results
MiR-9 expression in HCC tissues
MiR-9 expression was detected in 200 pairs of HCC
tissues and adjacent non-neoplastic liver tissues nor-
malized to RNU6B. As shown in Figure 1, we found
that the expression of miR-9 was markedly increased
in HCC tissues compared with non-neoplastic liver
tissues (mean ± SD: 7.26 ± 1.30 vs. 3.14 ± 1.08, P <
0.001, Figure 2a). In addition, miR-9 expression in
early stage (6.59 ± 1.33) and advanced stage (7.68 ±
1.13) HCC tissues were both significantly higher than
that in non-neoplastic liver tissues (3.14 ± 1.08; P < 0.0001
and <0.0001, respectively, Figure 2b and c). There was
also a significant difference in miR-9 expression be-
tween early stage and advanced stage HCC tissue speci-
mens (P < 0.001, Figure 2d).
Expression of miR-9 and clinicopathological features
We then analyzed the association between miR-9 ex-
pression and clinicopathological parameters in HCC.
HCC tissues expressing miR-9 at levels less than the me-
dian expression level (7.293) were assigned to the low
expression group (mean expression value 6.22, n = 100),
and those samples with expression above the median
value were assigned to the high expression group (mean
expression value 8.30, n = 100). The high level of miR-9
expression was significantly more common in HCC
tissues with advanced pathologic grade than those with
low pathologic grade (P = 0.0389, Table 1). Besides,
miR-9 up-regulation group has a higher rate of venous
infiltration (P < 0.0001). In this study, no significant
association between miR-9 expression and tumor size
was detected (P = 0.252). When the AFP status was
considered, the expression of miR-9 was not different
among the high and low level status (P = 0.127). No
significant association was found between miR-9 ex-
pression and gender or age at diagnosis.
MiR-9 expression and survival in patients with HCC
In the 5 years’ follow-up, the association between
miR-9 expression and prognosis was detected using
Kaplan–Meier method and log-rank test. The overall
survival of HCC patients with high miR-9 expression
was significantly shorter than that with low miR-9
expression (P < 0.0001, Figure 3a). When the patho-
logical stages were considered, the higher miR-9 ex-
pression was a risk of poor prognosis in both the earlystage of HCC (P = 0.0228, Figure 3b) and the advanced
HCC (P = 0.0062, Figure 3c).
Multivariate Cox proportional hazard analysis
In the Cox proportional hazard model, it was confirmed
that miR-9 expression in the biopsy samples (RR 4.28; 95%
CI, 2.77-7.23), tumor stage (RR 3.10; 95% CI, 1.22-4.77),
and venous infiltration (RR, 2.61; 95% CI, 1.34-5.12) were
predictor of poor prognosis of the patients with HCC.
Our results showed that age (RR, 1.60; RR, 0.40-2.65),
gender (RR, 1.53; 95% CI, 0.50-2.95), tumor size (RR,
2.25; 95% CI, 0.95-4.34), and AFP (RR, 1.38; 95% CI,
0.58-2.64) were not independent predictor of the sur-
vival of patients with HCC (Table 2).
Discussion
Although with the development of early diagnosis and sur-
gical techniques, the patients with hepatocellular carcinoma
Figure 3 Kaplan-Meier survival curves for HCC patients with high or low expression of miR-9. (a) The 5-year overall survival rate of all
200 HCC patients with high or low miR-9 expression; (b) The 5-year overall survival rate of 71 HCC patients with early stage in high or low miR-9
expression group; (c) The 5-year overall survival rate of 129 HCC patients with advanced stage in high or low miR-9 expression group.
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biomarkers for early diagnosis and predictor of prognosis
are desperately required now. A lot of work has been con-
ducted in an attempt to identify biomarkers with diagnostic
and prognostic implications for HCC. MiRNAs have been
demonstrated to be critical regulators of carcinogenesis and
tumor progression in HCC. The role of miR-9 as a prog-
nostic factor has been recently described in different tu-
mours, such as acute lymphocytic leukemia [30], acute
myeloid leukemia [31], and colon cancer [32]. Similarly in
the present study, we observed that miR-9 expression was
up-regulated in HCC tissues compared with noncancerous
liver tissues. The up-regulation of miR-9 in HCC cancer tis-
sues was also significantly correlated with aggressive clini-
copathological features. We found that the patients with
high miR-9 expression have an advanced tumor staging and
are in higher risk of venous infiltration. Moreover, the re-
sults of Kaplan–Meier analyses showed that HCC patients
with the high miR-9 expression tend to have shorter overall
survival and progression free survival. The multivariate ana-
lysis clearly indicated that the high miR-9 expression in bi-
opsy samples may be considered as an independent
prognostic factor in HCC for decreased survival.
MiR-9 is a regulator of neuronal progenitor cell fate
during neurogenesis [13,14], which has recently been im-
plicated in cancer [15]. Although most studies indicate a
tumour-suppressor activity for miR-9 in cancer cells [16],
conflicting data exist, and the outcome of miR-9 function
appears to be tumour specific [17]. Recent studies also re-
port that miR-9 is heterogeneously expressed within a
given tissue [23]. miR-9 is downregulated in breast cancer,
renal cell carcinoma, and gastric cancer due to promoter
methylation [18-20]. The transcriptional activity of miR-9
seems to be related to gene silencing by DNA methylation.
Previous studies have demonstrated that the high fre-
quency of hypermethylated CpG islands at miR-9 genes
resulted in down-regulation of miR-9 in human cancer
[20]. In addition, microRNA-9 is a methylation-silenced
tumour suppressor that could be a potential candidate
predictive marker for poor prognosis of medulloblastoma.Loss of microRNA-9 may confer a proliferative advantage
to tumour cells, and it could possibly contribute to disease
pathogenesis [33]. On the other hand, the down-
expression of miR-9 may be introduced by hypoxic stress,
resulting in alternative splicing shift to proangiogenic
isoforms of VEGF165 [34]. However, in contrast, miR-
9 has been found to be upregulated in various cancer
tissues like HCC, gliomas, and colorectal cancer
[21,22,35]. Previous study reported miR-9 may
possibly promote HCC migration and invasion
through regulation of KLF17 [35]. In the present
study, the up-expression of the miR-9 demonstrated
aggressive clinicopathological features, with the mech-
anism still unknown. Ma et al. have suggested a regu-
latory pathway of miR-9 as a metastasis-promoting
miRNA [24]. They demonstrated that miR-9 directly
targets CDH1, the E-cadherin- encoding mRNA, lead-
ing to down-regulation of E-cadherin and increase in
cancer cell motility and invasiveness [24]. Besides in-
duction of Epithelial-mesenchymal transition (EMT),
miR-9 was found to contribute to tumor angiogenesis,
another important mechanism in metastasis, through
activation of beta-catenin signaling pathway induced
by E-cadherin down-regulation [24]. Recently, they
also showed that miR-9 can function as a metastasis-
promoting miRNA even in the E-cadherin-negative
breast cancer cells through downregulation of leukemia
inhibitory factor receptor [36].
Conclusion
In conclusion, our results have demonstrated that the
levels of miR-9 are higher in HCC tissues than those in
matched normal liver tissues and correlated with disease
stage and the presence of venous infiltration. These find-
ings enhance our understanding of the role of miR-9 in
HCC progression and suggest that miR-9 may function
as microtumor promoter genes in HCC. These findings
suggest the potential clinical use of microRNA measure-
ments, particularly in estimating prognosis for patients
with HCC. Large well-designed studies with diverse
Cai and Cai Diagnostic Pathology  (2014) 9:1000 Page 6 of 6populations and functional evaluations are warranted to
confirm and extend our findings. Examining new targets
and other biological experiments will clarify the func-
tions and roles of microRNAs in HCC.Competing interests
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